Richard Nolan Townsend - 13 Mar 2026 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Executive Officer, Director
Signature
/s/ Youjin Choi, Attorney-in-Fact
Issuer symbol
LXEO
Transactions as of
13 Mar 2026
Net transactions value
$0
Form type
4
Filing time
17 Mar 2026, 21:22:39 UTC
Previous filing
20 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Townsend Richard Nolan Chief Executive Officer, Director C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK /s/ Youjin Choi, Attorney-in-Fact 17 Mar 2026 0001995218

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Award +2,623 +0.67% $2.64* 395,106 13 Mar 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
F2 Includes 261,349 Restricted Stock Units.